TXMD TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Company profile
Ticker
TXMD
Exchange
Website
CEO
Robert G. Finizio
Employees
Incorporated in
Location
Fiscal year end
Industry (SEC)
Former names
AMHN, Inc., Croff Enterprises Inc, Croff Oil Co
SEC CIK
Corporate docs
IRS number
870233535
Investment data
Securities sold
Number of investors
Calendar
24 Feb 20
4 Apr 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | 15.9M | 23.72M | 6.08M | 3.95M | |
| Net income | -49.44M | -31.97M | -55.24M | -39.51M | |
| Diluted EPS | -0.19 | -0.13 | -0.23 | -0.16 | |
| Net profit margin | -311% | -135% | -909% | -1001% | |
| Operating income | -44.39M | -27.07M | -41.64M | -38.11M | |
| Net change in cash | 5.5M | -27.52M | 59.96M | -38.73M | |
| Cash on hand | 160.83M | 155.33M | 182.85M | 122.88M | |
| Cost of revenue | 2.88M | 1.44M | 1.25M | 762.83K |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 49.65M | 16.1M | 16.78M | 19.36M | |
| Net income | -176.14M | -132.62M | -76.93M | -89.88M | |
| Diluted EPS | -0.72 | -0.59 | -0.37 | -0.46 | |
| Net profit margin | -355% | -824% | -458% | -464% | |
| Operating income | -151.21M | -130.22M | -77.63M | -90.25M | |
| Net change in cash | -783.36K | 34.48M | -4.4M | 66.83M | |
| Cash on hand | 160.83M | 161.61M | 127.14M | 131.53M | |
| Cost of revenue | 6.33M | 2.74M | 2.64M | 4.19M |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|
| 30 Mar 20 | Donegan Michael C | RSU Common Stock | Grant | Aquire A | 0 | 57,000 | 0 | 57,000 |
| 30 Mar 20 | Donegan Michael C | Performance Stock Units Common Stock | Grant | Aquire A | 0 | 57,000 | 0 | 57,000 |
| 30 Mar 20 | Milligan John C.K. IV | RSU Common Stock | Grant | Aquire A | 0 | 310,500 | 0 | 310,500 |
| 30 Mar 20 | Milligan John C.K. IV | Performance Stock Units Common Stock | Grant | Aquire A | 0 | 310,500 | 0 | 310,500 |
| 30 Mar 20 | Finizio Robert G | RSU Common Stock | Grant | Aquire A | 0 | 475,000 | 0 | 475,000 |
| 30 Mar 20 | Finizio Robert G | Performance Stock Units Common Stock | Grant | Aquire A | 0 | 475,000 | 0 | 475,000 |
| 30 Mar 20 | Krassan Mitchell | RSU Common Stock | Grant | Aquire A | 0 | 151,500 | 0 | 151,500 |
| 30 Mar 20 | Krassan Mitchell | Performance Stock Units Common Stock | Grant | Aquire A | 0 | 151,500 | 0 | 151,500 |
| 30 Mar 20 | Cartwright Daniel A | RSU Common Stock | Grant | Aquire A | 0 | 151,500 | 0 | 151,500 |
| 30 Mar 20 | Cartwright Daniel A | Performance Stock Units Common Stock | Grant | Aquire A | 0 | 151,500 | 0 | 151,500 |
Institutional ownership Q4 2019
70.9% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 171 |
| Opened positions | 32 |
| Closed positions | 14 |
| Increased positions | 56 |
| Reduced positions | 40 |
13F shares |
Current |
|---|---|
| Total value | 466.78M |
| Total shares | 192.45M |
| Total puts | 806K |
| Total calls | 914K |
| Total put/call ratio | 0.9 |
Largest owners |
Shares | Value |
|---|---|---|
| JPM JPMorgan Chase & Co. | 19.72M | $47.72M |
| N Price T Rowe Associates | 19.24M | $46.56M |
| BLK BlackRock | 18.26M | $44.19M |
| FMR | 17.68M | $42.78M |
| Vanguard | 16.6M | $40.16M |
| BK Bank Of New York Mellon | 13.12M | $31.75M |
| Rubric Capital Management | 11.01M | $26.65M |
| BEN Franklin Resources | 9.48M | $22.95M |
| Frontier Capital Management | 6.41M | $15.52M |
| STT State Street | 5.53M | $13.38M |
Financial report summary
?Competition
Mylan • Pfizer • AMAG Pharmaceuticals • Allergan • Agile Therapeutics • VMS • Allergan • Mylan • Amneal Pharmaceuticals • Amneal Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
Abbreviated, adjudicate, adjudicating, adjudication, affiliated, androgen, aspect, Azar, bind, BLA, blood, Blueprint, bore, bribe, broadening, bulk, calendar, capturing, CCPA, cGCP, charitable, Charity, chat, China, chosen, Circuit, Classic, codified, comfortable, Constant, construed, contemporaneously, copayment, count, covertly, custody, dialogue, disaster, dissatisfied, distraction, district, DSCSA, element, embedded, embezzling, endorsement, entirety, Epidemic, estate, EUR, explanation, extinguishment, Fighting, fleet, formatted, fullest, gave, GDPR, glucocorticoid, Haight, headquarter, heard, HHS, HITECH, house, HQ, hurricane, implicit, improperly, incentivize, inflationary, Inline, insignificant, insource, insourcing, instance, Interactive, invent, IP, Joyesta, judgement, KAM, labor, laid, language, learn, Lending, lien, lubrication, match, mathematical, member, mission, mode, modification, moral, NaN, needy, nonprescription, Northern, notably, objectionable, obstructing, OCR, offense, OIG, Opioid, opposition, optimistic, overhead, overtly, pair, PAP, PBM, PDMA, pedigree, penalty, Petersburg, pharmacopogical, PhRMA, Pledge, PlushCare, pocket, pregestational, PTE, Puerto, push, Recovery, redacted, redeemed, reinspected, reinstating, remanded, remote, repaid, Rico, Road, role, Rulemaking, Ryan, SA, se, Senate, senior, serverable, ShareholdersTherapeuticsMD, SM, solution, sponsorship, St, steady, stealing, StockholdersTherapeuticsMD, stronger, struck, superseded, Switzerland, synergistic, Tao, TCJA, telehealth, telemedicine, tendered, Theramex, timeline, TPG, tracing, transmit, trick, UK, unallocated, unaudited, unexpired, uninsured, upfront, verifying, Veteran, vigorously, vulvovaginal, withdrawn, withheld, wrote, XBRL, Yamato
Removed:
academic, advice, allergenic, allocating, Alternatively, anemia, banking, bone, bringing, Broken, capable, carcinoma, centralization, childbirth, Climacteric, commercialized, compelled, contrast, conventional, cooperating, Cowen, cure, decided, declined, defer, delaying, demographic, density, deployment, diagnose, dosage, dosed, emulsion, encountered, England, Epidemiological, Equivalence, EvaluatePharma, expediting, expressly, female, fracture, function, hysterectomy, implicitly, inactive, intercourse, irritation, itching, journal, justify, Lancet, lengthen, leveraging, lived, located, masking, Master, mater, Medicine, metastatic, mineral, mutually, Noven, NW, outbound, Outlook, outreach, ovariectomized, painful, palliative, Parkway, pearl, penetrated, premarket, preterm, Preview, principle, prioritize, progestational, Prometrium, proposal, propose, quantify, ratable, recurrent, RediChew, remained, renal, rendered, replacement, Rx, Sancilio, SCI, send, shipment, shorten, slight, slightly, Sound, SPRY, stopped, strive, substantiating, substitutable, suggested, suit, suppository, SYMBODA, theoretically, thereunder, therewith, topical, treated, trillion, truthful, undergo, updating, urination, virtually, vitaPearl, vitaTrue, Woodstock, worldwide
Financial reports
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
30 Jul 18
10-Q
2018 Q1
Quarterly report
7 May 18
10-K
2017 FY
Annual report
23 Feb 18
10-Q
2017 Q3
Quarterly report
7 Nov 17
Current reports
8-K
TherapeuticsMD Provides COVID-19-Related Business Update
26 Mar 20
8-K
Departure of Directors or Certain Officers
24 Mar 20
8-K
Regulation FD Disclosure
3 Mar 20
8-K
TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
20 Feb 20
8-K
Building the Premier Women’s Health Company JP Morgan Conference January 2020
14 Jan 20
8-K
TherapeuticsMD Announces Amendment to
30 Dec 19
8-K
Regulation FD Disclosure
18 Dec 19
8-K
Regulation FD Disclosure
19 Nov 19
8-K
TherapeuticsMD Announces Third Quarter 2019 Financial Results
6 Nov 19
8-K
Entry into a Material Definitive Agreement
29 Oct 19
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
24 Feb 20
424B2
Prospectus for primary offering
25 Oct 19
FWP
Free writing prospectus
24 Oct 19
FWP
Free writing prospectus
23 Oct 19
424B5
Prospectus supplement for primary offering
23 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Jun 19
S-8
Registration of securities for employees
21 Jun 19
424B2
Prospectus for primary offering
2 Aug 18
424B2
Prospectus for primary offering
2 Aug 18
424B5
Prospectus supplement for primary offering
31 Jul 18
Proxies
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
25 Apr 17
DEFA14A
Additional proxy soliciting materials
25 Apr 17
DEF 14A
Definitive proxy
28 Apr 16
DEFA14A
Additional proxy soliciting materials
28 Apr 16
DEF 14A
Definitive proxy
30 Apr 15
DEFA14A
Additional proxy soliciting materials
30 Apr 15
Other
CT ORDER
Confidential treatment order
10 Apr 19
CT ORDER
Confidential treatment order
12 Dec 18
CT ORDER
Confidential treatment order
21 Aug 18
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
31 Jan 17
UPLOAD
Letter from SEC
25 Jan 17
CORRESP
Correspondence with SEC
29 Dec 16
UPLOAD
Letter from SEC
15 Dec 16
EFFECT
Notice of effectiveness
17 Nov 15
CORRESP
Correspondence with SEC
13 Nov 15
Ownership
4
TherapeuticsMD / John C.K. IV Milligan ownership change
2 Apr 20
4
TherapeuticsMD / Robert G Finizio ownership change
2 Apr 20
4
TherapeuticsMD / Mitchell Krassan ownership change
2 Apr 20
4
TherapeuticsMD / Daniel A Cartwright ownership change
2 Apr 20
4
TherapeuticsMD / Michael C Donegan ownership change
2 Apr 20
3
TherapeuticsMD / Gail K Naughton ownership change
27 Mar 20
3
TherapeuticsMD / PAUL BISARO ownership change
27 Mar 20
SC 13G/A
TherapeuticsMD, Inc.
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
TherapeuticsMD, Inc.
7 Feb 20
Patents
APP
Utility
Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods
5 Mar 20
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
GRANT
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
25 Feb 20
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
GRANT
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
21 Jan 20
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.
GRANT
Utility
Steroid hormone pharmaceutical composition
14 Jan 20
This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.
APP
Utility
Progesterone Formulations Having a Desirable PK Profile
19 Dec 19
This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters.